Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GSK

Pfizer To Quit GSK's Consumer Health JV Following Its Spin-Off

Pfizer Inc. (NYSE:PFE) intends to sell its 32% investment in Haleon, a consumer health joint venture with GSK plc (NYSE:GSK), after the business is spun out as an independent listed company in July, reported Reuters. Pfizer had previously indicated that it might seek to sell its stake in Haleon, a consumer health company and…

Benzinga

Unilever Jumps After Nelson Peltz Joins Board

Unilever plc (NYSE: UL) shares traded higher by 8% on Tuesday after the company announced activist investor Nelson Peltz is joining the company's board of directors.

Benzinga

GSK strikes deal to buy US vaccine firm Affinivax

It comes as the UK pharmaceutical business seeks to bolster its vaccine operation as part of a shake-up of its portfolio.

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

GSK looking to invest more in Hyderabad

KTR holds discussions with Global R&D Head of GSK Consumer Health in London

The Hindu

3 Healthcare Stocks That Pay Dominant Dividends

Despite heightened market volatility, the healthcare industry is expected to grow significantly in 2022 amid surging chronic diseases worldwide, an aging population, increasing healthcare expenditure, and numerous medical advancements. So, we think it could be wise to invest in fundamentally sound healthcare stocks Gilead (GILD), Takeda (TAK), and GlaxoSmithKline (GSK).…

StockNews.com

ARWR: Phase 3 PALISADE Study of ARO-APOC3 Underway…

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT

Benzinga

GlaxoSmithKline: Dividend Insights

Wednesday marks the last chance for investors to receive the next dividend payout from GlaxoSmithKline (NYSE:GSK).

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Hundreds of organisations breached patient data rules, reveals BMJ

Drug firms, private healthcare providers and universities among those that may be failing to protect confidentiality, says report

The Guardian - UK

Boots, Superdrug and other chemists report hay fever pill shortages

GlaxoSmithKline blames shortage of key ingredient for lack of Piriton and Piriteze tablets

The Guardian - UK

3 High-Yield Dividend Stocks to Buy in May: GlaxoSmithKline, A.P. Moeller-Maersk, and ENI

With the latest federal interest rate hike and the possibility of further monetary policy tightening, market indices have been going haywire. Because volatility is expected to persist, with experts fearing the economy will slip into recession, we think it could be wise to bet on high dividend-yielding stocks GlaxoSmithKline (GSK),…

StockNews.com

GlaxoSmithKline Clocks 32% Topline Growth Buoyed By COVID-19 Therapy, Shingrix Vaccine

GlaxoSmithKline Plc's (NYSE:GSK) Q1 turnover reached £9.78 billion, up 32% Y/Y on actual exchange rate AER and constant exchange rate CER basis. Specialty Medicines turnover was £3.13 billion, up 98% AER, 97% CER (+16% AER, 15% CER excluding Xevudy), driven by consistent growth in all therapy areas, including sales of Xevudy. Sales…

Benzinga

Recap: GlaxoSmithKline Q1 Earnings

GlaxoSmithKline (NYSE:GSK) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

GlaxoSmithKline's Earnings Outlook

GlaxoSmithKline (NYSE:GSK) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that GlaxoSmithKline will report an earnings per share (EPS) of $0.76.

Benzinga

The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Sierra Oncology Stock Is Soaring: Here's Why

Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in cash, representing an a

Evening Standard

GSK buys US-based cancer specialist Sierra Oncology for $1.9 billion

Deal is in step with GSK’s strategy of building a strong portfolio of new specialty medicines and vaccines

Benzinga

GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal

GlaxoSmithKline plc (NYSE:GSK) has agreed to acquire Sierra Oncology Inc (NASDAQ:SRRA) for $55 per share in cash, representing an approximate total equity value of $1.9 billion (£1.5 billion). Sierra's momelotinib complements GSK's Blenrep (belantamab mafodotin), building on GSK's commercial and medical expertise in hematology. If momelotinib is approved, GSK expects momelotinib will contribute to GSK's growing…

Benzinga

Germany Inks COVID-19 Vaccine Deal With CureVac, GSK Until 2029

Germany has signed a contract with CureVac BV (NASDAQ:CVAC) and its partner GlaxoSmithKline plc (NYSE:GSK) for domestically produced mRNA vaccines to bolster supplies for pandemic preparedness. The five-year contract allows for the production of up to 80 million doses at short notice until 2029, CureVac said, adding that those doses could be for the remainder of…

Get all your
news in one place.

100’s of premium titles.
One news app.

Insider UK

Edinburgh University spin-out bags £9 million financing

Money includes a £2.5m Innovate UK grant to fund human clinical trials of its technology

Benzinga

Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here

The U.S. health regulator said GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) antibody therapy was no longer authorized as a COVID-19 treatment. The decision was made as the CDC now estimates that the proportion of Covid-19 cases caused by BA.2 is above 50% nationwide. "Sotrovimab is no longer authorized to treat COVID-19 in any…

Reuters

Governments want COVID vaccine developers to aim higher in hunt for better shots

As governments prepare to live with COVID-19, some are questioning how much to rely on drugmakers to adapt vaccines to ward off future virus variants amid signs of tension between companies and regulators over the best approach, according to several sources familiar with the matter.

Benzinga

CureVac - GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial

CureVac N.V. (NASDAQ:CVAC) dosed the first participant in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed with GlaxoSmithKline plc (NYSE:GSK). The clinical trial is expected to provide valuable data to evaluate further the performance of CureVac’s second-generation mRNA backbone, which has the potential to be applied broadly in future vaccines against…

Benzinga

EMA Starts Review Of Sanofi-GlaxoSmithKline's COVID-19 Vaccine

The European Medicines Agency has started reviewing Sanofi SA (NASDAQ:SNY) and its partner GlaxoSmithKline Plc's (NYSE:GSK) application seeking conditional authorization for their COVID-19 vaccine. The vaccine candidate, Vidprevtyn, was already being evaluated under a rolling review by EMA. The drugmakers had earlier said that they would seek regulatory approval for their COVID-19 vaccine to be…

Benzinga

FDA Approves ViiV Healthcare's Cabenuva For Virologically Suppressed Adolescents With HIV

The FDA has approved ViiV Healthcare's Cabenuva (cabotegravir, rilpivirine) for HIV-1 in virologically suppressed adolescents. The approval covers patients aged 12 years or older and weighing at least 35kg on a stable antiretroviral regimen, with no history of treatment failure and no known or suspected resistance to either cabotegravir or rilpivirine. The regimen…

Benzinga

FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant

The FDA said that the currently authorized 500mg dose of GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) COVID-19 antibody therapy is unlikely to be effective against the omicron BA.2 variant. The agency updated its website to exclude sotrovimab use in geographic regions where the infection is likely caused by the omicron BA.2 variant. GSK…

1 … 11 12 13 14

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.